Diphtheria Therapeutic and Drug Pipeline Review H2



Wise.Guy.

Diphtheria Treatment Pipeline Review H2 2016

PUNE, INDIA, November 21, 2016 /EINPresswire.com/ — Get Sample Report @ https://www.wiseguyreports.com/sample-request/752819-diphtheria-pipeline-review-h2-2016

Diphtheria is a bacterial infection that affects the membranes of the throat and nose. If left untreated, diphtheria can cause severe damage to kidneys, nervous system, and heart. Symptoms include sore throat and hoarseness, swollen glands (enlarged lymph nodes) in neck, nasal discharge, fever and chills and malaise. Treatment includes antitoxins and antibiotics.

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Diphtheria – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Diphtheria (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diphtheria (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Diphtheria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 10, 1, 5, 1, 7 and 3 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 2 molecules, respectively.Diphtheria.

Diphtheria (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Diphtheria (Infectious Disease).
– The pipeline guide reviews pipeline therapeutics for Diphtheria (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Diphtheria (Infectious Disease) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Diphtheria (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Diphtheria (Infectious Disease)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Diphtheria (Infectious Disease).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Diphtheria (Infectious Disease) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Diphtheria Overview 9
Therapeutics Development 10
Pipeline Products for Diphtheria – Overview 10
Pipeline Products for Diphtheria – Comparative Analysis 11
Diphtheria – Therapeutics under Development by Companies 12
Diphtheria – Therapeutics under Investigation by Universities/Institutes 14
Diphtheria – Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Diphtheria – Products under Development by Companies 18
Diphtheria – Products under Investigation by Universities/Institutes 20
Diphtheria – Companies Involved in Therapeutics Development 21
Beijing Minhai Biotechnology Co., Ltd 21
BioClonetics Immunotherapeutics, Inc. 22
…Continued

Access Report @ https://www.wiseguyreports.com/reports/752819-diphtheria-pipeline-review-h2-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Irritable Bowel Syndrome Therapeutic and Drug Pipeline Review H2



Wise.Guy.

Irritable Bowel Syndrome Treatment Pipeline Review H2 2016

PUNE, INDIA, November 21, 2016 /EINPresswire.com/ — Get Sample Report @ https://www.wiseguyreports.com/sample-request/752817-irritable-bowel-syndrome-pipeline-review-h2-2016
Inflammatory Bowel Diseases (IBD) is a broad term that describes conditions with chronic or recurring immune response and inflammation of the gastrointestinal tract. Signs and symptoms include abdominal cramps and pain, diarrhea that may be bloody, weight loss, loss of appetite and fever. The predisposing factors include age, family history, smoking and some pain killers. Treatment includes corticosteroids, immune suppressors, antibiotics and pain relievers.

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Irritable Bowel Syndrome – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Irritable Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 10, 6, 9 and 1 respectively.Irritable Bowel Syndrome.

Irritable Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome (Gastrointestinal).
– The pipeline guide reviews pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Irritable Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Irritable Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Irritable Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Irritable Bowel Syndrome Overview 10
Therapeutics Development 11
Pipeline Products for Irritable Bowel Syndrome – Overview 11
Irritable Bowel Syndrome – Therapeutics under Development by Companies 12
Irritable Bowel Syndrome – Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Irritable Bowel Syndrome – Products under Development by Companies 17
Irritable Bowel Syndrome – Companies Involved in Therapeutics Development 19
4D Pharma Plc 19
A. Menarini Industrie Farmaceutiche Riunite Srl 20
…Continued

Access Report @ https://www.wiseguyreports.com/reports/752817-irritable-bowel-syndrome-pipeline-review-h2-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Indian Non-IP CCTV Camera Market to Reach INR 38.65 crore with 27.16% CAGR Forecast to 2021

Non-IP CCTV Camera Market 2016 Indian Trends, Market Share, Industry Size, Growth, Opportunities, and Forecast to 2021

PUNE, INDIA, November 21, 2016 /EINPresswire.com/ — Closed Circuit Television (CCTV) is a system which uses cameras to transmit signal to a specific place which helps to monitor any kind of activities going on in any area. CCTV is a growing market as it is being widely used in many applications all over the world. Technology is the main concern in the CCTV camera market in India. IP (Internet Protocol) and non-IP CCTV cameras are the two types of CCTV cameras that are traditionally used. Now based on the different type of camera used, bifurcation is made like dome cameras, bullet and box shaped cameras, PTZ cameras etc. CCTV cameras was primarily used in the commercial segment for the surveillance, but with increasing thefts, burglary and other criminal activities all over the world, residential sector is also showing keen interest in the CCTV camera market for security purpose. This report is about the market size of the CCTV camera market in India how with the increasing number of terrorist activities, the demand of CCTV market is continuously increasing. This report describes the different technologies that are used in the CCTV market and the upcoming technologies that would drive the market. The report also reveals the trend in this industry is shifting to people becoming more conscious about the security and the increasing thefts than being pessimist about the cost involved in buying the product.
Request a sample report @ https://www.wiseguyreports.com/sample-request/744785-india-non-ip-cctv-camera-market-outlook-2021
The India CCTV camera market is anticipated to generate substantial revenue of about INR 38.65 crore till 2021. Asia Pacific and America holds the largest share of the India market and act as one of the main driver for the market. India and China are the countries with the highest potential for the CCTV camera market. Technology-wise, wireless CCTV cameras are becoming a trend apart from the traditional non-IP and IP which is widely used currently. Non –IP technology consisting of analog and HD CCTV cameras dominate the market currently. Dome shaped cameras dominate the CCTV market in terms of type of camera used. PTZ (pan, tilt, zoom) is a recent technology which allows a 360 degree view of the surveillance are and also gives added features to zoom by covering a larger section of area.
According to “India CCTV Camera Non-IP Market Outlook, 2021”, the India CCTV Camera market is expected to grow with a CAGR of about 27.16% in the period from 2016 to 2021. Technology wise non-IP dominates the Indian market but in the coming years. Analog is technology which is in a depleting stage and its share is expected to be taken by the IP technology and the HD type CCTV camera. Dome typed cameras are the most widely used cameras in any sectors. Commercial segment is the driver of the CCTV market in India with the increasing count of SOHO’s and SME’s. With the increasing security concerns, residential sector would also be one of the factors for the increasing market. As criminal activities are more in the northern region of India, North dominates the market in terms of revenue. According to the technology different players are present in the market. In the non-IP segment the market is consisting of players like CP Plus, Dahua and Prama Hikvision constituting to more than 70% of the market. The widespread use of CCTV camera in various industries like government sectors, SOHO’s and SME’s, Banking, Hospitality and other commercial establishment will make the CCTV cameras market to increase with a robust growth.
Complete report details @ https://www.wiseguyreports.com/reports/744785-india-non-ip-cctv-camera-market-outlook-2021
Key points in table of content
1. Executive Summary
2. India CCTV Camera Market Outlook
2.1. Market Size By Value
2.2. Market Share
2.2.1. By Country
2.2.2. By Geography
2.2.3. By Technology
2.2.4. By Company
3. India Electronic Security Market Outlook
3.1. Market Size By Value
3.2. Market Share By Segment
4. India CCTV Camera Market Outlook
4.1. Market Size By Value with technology division
4.2. Market Size By Volume with technology division
4.3. Market Share
4.3.1. By End User Segment
4.3.2. By Region
4.3.3. By Industry
4.3.4. By City
5. India Non – IP CCTV Market Outlook
5.1. Market Size
5.1.1. By Value
5.1.2. By Volume
5.2. Market Share
5.2.1. By Company
5.2.2. By Segment
5.2.3. Analog CCTV Market Outlook
5.2.3.1. Market Size By Value
5.2.3.2. Market Size By Volume
5.2.3.3. By Camera Type
5.2.4. HD CCTV Market Outlook
5.2.4.1. Market Size By Value
5.2.4.2. Market Size By Volume
5.2.4.3. By Camera Type
5.3. Organized vs. Unorganized Market Outlook
5.4. Pricing Analysis
6. India Economic Profile
7. Channel Partner Analysis
8. Market Trends & Developments
8.1. Thermal Cameras
8.2. Video Analytics
8.3. Cloud Video Surveillance
8.4. 360 degree camera
9. Competitive Landscape
9.1. Porters Five Forces
9.2. Company Profiles
9.2.1. CP PLUS gmbh & Co. KG.
9.2.2. Dahua Technology Co. Ltd.
9.2.3. Honeywell International Inc.
9.2.4. Panasonic Corporation
9.2.5. Prama Hikvision India Pvt. Ltd.
9.2.6. Micro Technology India Pvt. Ltd.
9.2.7. Zicom Security System
10. Disclaimer
Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=744785
Contact US:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Critical Limb Ischemia Therapeutic and Drug Pipeline Review H2



Wise.Guy.

Critical Limb Ischemia Treatment Pipeline Review H2 2016

PUNE, INDIA, November 21, 2016 /EINPresswire.com/ — Get Sample Report @ https://www.wiseguyreports.com/sample-request/752815-critical-limb-ischemia-pipeline-review-h2-2016

Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that result in reduced blood flow to the legs, feet and hands. Symptoms include pain or numbness in feet or toes, sores, skin infections will not heal. Treatment goals for CLI include reducing the number of cardiovascular risk factors (such as quitting smoking and reduction of cholesterol), relieving pain, healing ulcers, preventing major amputation, improving quality of life and increasing survival.

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Critical Limb Ischemia – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Critical Limb Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Critical Limb Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 11, 4, 12 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Critical Limb Ischemia.

Critical Limb Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Critical Limb Ischemia (Cardiovascular).
– The pipeline guide reviews pipeline therapeutics for Critical Limb Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Critical Limb Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Critical Limb Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Critical Limb Ischemia (Cardiovascular)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Critical Limb Ischemia (Cardiovascular).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Critical Limb Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Critical Limb Ischemia Overview 10
Therapeutics Development 11
Pipeline Products for Critical Limb Ischemia – Overview 11
Pipeline Products for Critical Limb Ischemia – Comparative Analysis 12
Critical Limb Ischemia – Therapeutics under Development by Companies 13
Critical Limb Ischemia – Therapeutics under Investigation by Universities/Institutes 15
Critical Limb Ischemia – Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Critical Limb Ischemia – Products under Development by Companies 19
Critical Limb Ischemia – Products under Investigation by Universities/Institutes 21
Critical Limb Ischemia – Companies Involved in Therapeutics Development 22
AnGes MG, Inc. 22
Apceth GmbH & Co. KG 23
Athersys, Inc. 24
BiogenCell Ltd. 25
Caladrius Biosciences Inc 26
Cynata Therapeutics Limited 27
…Continued

Access Report @ https://www.wiseguyreports.com/reports/752815-critical-limb-ischemia-pipeline-review-h2-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Rubella Therapeutic and Drug Pipeline Review H2



Wise.Guy.

Rubella Treatment Pipeline Review H2 2016

PUNE, INDIA, November 21, 2016 /EINPresswire.com/ — Get Sample Report @ https://www.wiseguyreports.com/sample-request/752812-rubella-german-measles-pipeline-review-h2-2016

Rubella also known as the German measles is an acute, contagious viral infection. The rubella virus is transmitted by airborne droplets when infected people sneeze or cough. Symptoms include fever, headache, stuffy or runny nose, inflamed, red eyes, aching joints and enlarged, tender lymph nodes at the base of the skull, the back of the neck and behind the ears.

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Rubella (German Measles) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Rubella (German Measles) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rubella (German Measles) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rubella (German Measles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 2, 1, 2, 1 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.Rubella (German Measles).

Rubella (German Measles) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Rubella (German Measles) (Infectious Disease).
– The pipeline guide reviews pipeline therapeutics for Rubella (German Measles) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Rubella (German Measles) (Infectious Disease) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Rubella (German Measles) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Rubella (German Measles) (Infectious Disease)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Rubella (German Measles) (Infectious Disease).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Rubella (German Measles) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Rubella (German Measles) Overview 6
Therapeutics Development 7
Pipeline Products for Rubella (German Measles) – Overview 7
Pipeline Products for Rubella (German Measles) – Comparative Analysis 8
Rubella (German Measles) – Therapeutics under Development by Companies 9
Rubella (German Measles) – Therapeutics under Investigation by Universities/Institutes 10
Rubella (German Measles) – Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Rubella (German Measles) – Products under Development by Companies 15
Rubella (German Measles) – Products under Investigation by Universities/Institutes 16
Rubella (German Measles) – Companies Involved in Therapeutics Development 17
Beijing Minhai Biotechnology Co., Ltd 17
…Continued

Access Report @ https://www.wiseguyreports.com/reports/752812-rubella-german-measles-pipeline-review-h2-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Methicillin-Susceptible Staphylococcus aureus Therapeutic and Drug Pipeline Review H2



Wise.Guy.

Methicillin-Susceptible Staphylococcus aureus Treatment Pipeline Review H2 2016

PUNE, INDIA, November 21, 2016 /EINPresswire.com/ — Get Sample Report @ https://www.wiseguyreports.com/sample-request/752811-methicillin-susceptible-staphylococcus-aureus-review-h2-2016

Methicillin-Susceptible Staphylococcus aureus (MSSA) is a bacterium that is resistant to many antibiotics. MSSA usually cause skin infections, but can also cause pneumonia, and other serious types of infections. Symptoms include cellulitis, painful rashes, nausea and vomiting, fever, muscle aches, diarrhea and abdominal pain. Predisposing factors include weakened immune systems, burns and surgical wounds.

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections.

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease).
– The pipeline guide reviews pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Overview 6
Therapeutics Development 7
Pipeline Products for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Overview 7
Pipeline Products for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Comparative Analysis 8
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Therapeutics under Development by Companies 9
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Therapeutics under Investigation by Universities/Institutes 10
…Continued

List of Tables
Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, H2 2016 7
Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
…Continued

List of Figures
Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, H2 2016 7
Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
…Continued

Access Report @ https://www.wiseguyreports.com/reports/752811-methicillin-susceptible-staphylococcus-aureus-review-h2-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Acute Lymphocytic Leukemia Therapeutic and Drug Pipeline Review H2



Wise.Guy.

Acute Lymphocytic Leukemia Treatment Pipeline Review H2 2016

PUNE, INDIA, November 21, 2016 /EINPresswire.com/ — Get Sample Report @ https://www.wiseguyreports.com/sample-request/752809-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-pipeline-review-h2-2016

Acute lymphocytic leukemia (ALL) is the cancer of the white blood cells due to the production of a large number of immature lymphocytes thus blocking the production of normal blood cells. It enters the blood stream and rapidly progress to other parts of the body such as spleen, lymph nodes and liver. Risk factors for ALL include exposure to radiation or chemicals, age, virus infections and genetic factors. Symptoms include anemia, frequent infections, easy bruising, bone pain and breathing problems. Treatment includes chemotherapy, transfusions, transplant and medications.

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Acute Lymphocytic Leukemia – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Acute Lymphocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Lymphocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 3, 46, 42, 65 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 6, 14 and 2 molecules, respectively.Acute Lymphocytic Leukemia.

Acute Lymphocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Lymphocytic Leukemia (Oncology).
– The pipeline guide reviews pipeline therapeutics for Acute Lymphocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Acute Lymphocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Acute Lymphocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Acute Lymphocytic Leukemia (Oncology)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Acute Lymphocytic Leukemia (Oncology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Acute Lymphocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
Table of Contents 2
Introduction 7
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Overview 8
Therapeutics Development 9
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Therapeutics under Development by Companies 11
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Therapeutics under Investigation by Universities/Institutes 18
…Continued

List of Tables
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H2 2016 29
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Comparative Analysis, H2 2016 30
Number of Products under Development by Companies, H2 2016 31
…Continued

List of Figures
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H2 2016 29
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Comparative Analysis, H2 2016 30
Number of Products under Development by Companies, H2 2016 31
Number of Products under Investigation by Universities/Institutes, H2 2016 38
…Continued

Access Report @ https://www.wiseguyreports.com/reports/752809-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-pipeline-review-h2-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Hilarious Hit Bob’s Holiday Office Party Opens December First in LA

Cast: (L-R) Standing L-R David Bauman, Pat O’Brien, Rob Elk, Mark Fite, Sirena Irwin, Seated L-R Andrea Hutchman, Melissa Denton, Maile Flanagan, Joe Keyes. Photo by: Marissa Dramissi

Cast: (L-R) Rob Elk and Pat O’Brian Photo by: Ed Krieger

If there is one Christmas party that you shouldn’t miss this year, it’s “Bob’s Holiday Office Party!”

Irreverent, crude and devastatingly funny!

— Los Angeles Times

LOS ANGELES, CALIFORNIA, UNITED STATES, November 20, 2016 /EINPresswire.com/ — Playwrights Joe Keyes and Rob Elk are proud to bring back the longest running Holiday hit, Bob’s Holiday Office Party. Now in their twenty-first year, this hilarious and irreverent comedy has become a vital part of every Christmas season in Los Angeles since 1995. 12 performances only at The Atwater Village Theatre, 3269 Casitas Avenue, Los Angeles, 90039. Reservations at on Brown Paper Tickets. Bob's Holiday Office Party opens December 1, 2016 and runs through December 18, 2016. Thursday through Saturday at 8:00 PM, Sundays. at 7:00 PM.
IMPORTANT There will be no show Sunday, December 11. Monday, December 12 showtime is 8:00 PM. Tickets are $30 with preferred seating for $34.99.

Every year, insurance agent Bob Finhead's whacked out friends and clients stop by his small-town Iowa office for their annual holiday bash. The town mayor, the sheriff, the twin farmer sisters, the stoner, the town floozy and the pastor's wife have already RSVPed for this year's event. But Bob has dreams of a bigger life and wants to escape their narrow-minded thinking. Will he be able to fulfill his dream of becoming a professional inventor and move to the big city, or will he come to realize how much he is the heart and soul of the town? Will any of this matter once the party starts, the bickering and fighting begins, and the drinks hit the floor?

The play is set in the office of insurance salesman Bob Finhead in Neuterburg, Iowa (population 382). Bob is carrying on a flirtation with the mayor’s wife, while the mayor himself is busy accommodating a male houseguest.

Joe, the alcoholic town sheriff, is attracted to Brandy, the town party girl who is the twin sister of Carol, the minister’s emotionally disturbed wife. There’s one other set of twins in town, La Donna and La Voris Johnson, wealthy farmers who are proud members of the Neuterburg Tea Party.

The show is written by Joe Keyes and Rob Elk. Director Matt Roth’s Cast will include Elk & Keyes and the two are joined by returning cast members David Bauman, Cody Chappell*, Melissa Denton, Mark Fite*, Maile Flanagan, Andrea Hutchman, Sirena Irwin, Pat O'Brien*, Pat Towne*, Michael Halpin*, and Mary Scheer*. All are veterans of the Bob’s madness.

*Alternating Cast Member

Sandra Kuker
Kuker & Lee PR
(310) 652.7222
email us here

Bob’s Holiday Office Party


Source: EIN Presswire

Hello Stranger: How Interacting With Strangers Is On The Rise

Surging Social Media App Stocks Capitalize on Brazen Users

VANCOUVER, BRITISH COLUMBIA, CANADA, November 21, 2016 /EINPresswire.com/ — While most of the internet is familiar with names like Mark Zuckerberg of Facebook [NASDAQ: FB], or Sergey Brin and Larry Page of Alphabet Inc. (or “Google”) [NASDAQ: GOOG], there’s a good chance that the next big names in software growth stories will come out of China.

It’s been a hot month for Chinese smartphone app developers, including for the messaging apps from Momo Inc. [NASDAQ: MOMO] and YY Inc. [NASDAQ: YY].

Boosted by a surge in popularity for both developers by Asian market users, both Momo and YY saw Credit Suisse initiate coverage on their companies with outperform ratings.

Momo in particular saw a record high $25.62 earlier this month, which was a doubling in price over the last two months. YY’s company Q2 year over year revenue had tripled, driven by the launch of its live video service in Q3 of last year.

Longer established YY has also seen gains, matching a 4-month high of $55.92 on September 2, and currently sitting comfortably at $54.48 prior to Monday’s market open. This is significantly higher from a summer low of $31 in late July.

While YY is more established, it’s Momo that’s got the steadiest momentum at the moment, and has already reached a milestone of nearly 70 million monthly active users.

Unlike internet giants Facebook and Twitter [NYSE: TWTR], Momo and YY allowed public traders in on the story at an earlier stage. Both Facebook and Twitter did most of their major growth as private companies, only opening the door to the public through major IPOs that were already at high-end established prices.

For investors looking to capitalize on social messaging app development, both Momo and YY are looking like they’re here to stay. Driven by a deep pool of heavy-users in Asian markets, it’s reasonable to believe that the next big app will come from this part of the world, instead of the West.

Momo the Chameleon

When it first came on the scene, Momo was looked at (somewhat incorrectly) as a mere hookup app. However, the app gained a lot of its traction through its diverse types of interactions.

For instance, users of Momo have branched into using the app for music recommendations, and to support local musicians. Fans of bands can help build a groundswell of popularity for new songs, or also to shower the bands with praise in the form of micro-gifting.

In fact, Momo gains a lot of its revenue from users buying each other digital gifts, like flower bouqets, and yachts. Whereas, North American users don’t typically make as many micro purchases, they’re more inclined to purchase upgrades, and spinoff software.

In the case of Momo, the company’s stock went on a steady 66% price uptick after the company introduced live video service. The rise was more a steady incline, rather than a day of spiking.

How did one upgrade to the app result in such a steady growth spurt?

Adding live video basically tripled the company’s revenue, accounting for $57.9 million of the company’s $99 million in revenue. Just the live video revenue alone in Q2 of this year was as big as the company’s total revenue in the first half of last year.

The Next Momo?

While Momo has been using its geolocation-based interaction advantage to compete with the WhatsApps and Facebook Messengers out there, the app is inherently limited by user proximity.

Steadily growing, but still at an earlier stage, is a somewhat competing app called Hello Pal: SPEAK TO THE WORLD by Hello Pal International Inc. [CSE: HP] [OTC: HLLPF] [Frankfurt: 27H.F].

Unlike Momo, Hello Pal is geared towards making connections outside of the user’s general vicinity. Instead of talking only to the people within blocks of you, now Hello Pal users can have real-time conversations with people in other countries, and in other languages.

Developed by President and CEO, KL Wong, Hello Pal encourages users to reach out to people all over the world, to make new connections, and pick up new languages along the way.

Wong’s had success with language software in the recent past, having developed the award-winning Brillkids program. Brillkids helped parents inspire their very young children to learn language skills like reading, as well as basic mathematics, all at a tender age.

Videos of Wong’s own daughter breezing through reading demonstrations, and solving math problems at a pace usually reserved for child prodigies. Now Wong and his team are bridging some of the basics of Brillkids into HelloPal’s language learning process, while incorporating more social messaging characteristics on top.

The app has so far been a near instant success, as it continues to grow and climb through the ranks of many online app stores.

HelloPal has grown quite rapidly, with new users signing on at a rate between 3,500 and 6,000 per day. It was impressive that it reached 670,000 users within its first year since launch, as recently as June of this year. It’s even more impressive that it’s nearly doubled that number in just two and half months to a recently announced total of more than 1.2 million as of mid-September.

Much like Momo’s live video capability was a boost to the already popular app, Hello Pal is set to release a complimentary program focused more on travelers with the upcoming Travel Pal spinoff. Given that the app already has highly capable voice recognition in place, real-time language help for travelers outside of their normal comfort zones will have their confidence boosted by the app in their pocket.

Get the Hello Pal App here.

http://tinyurl.com/gqy3652

Braden Macke
Hello Pal International
604 683-0911
email us here


Source: EIN Presswire

LIOR BEN-HUR ANNOUNCES THE RELEASE OF A NEW ALBUM, SO I WANDER, ON FEBRUARY 10, 2017 [FREE SONG DOWNLOAD]

Worldwide release on February 10, 2017

San Francisco reggae/world music band

Lior Ben-Hur new album, So I Wander, is a Reggae/World music album produced by Marcus Urani of Groudation & Rising Tide

SAN FRANCISCO, CALIFORNIA, UNITED STATES, November 20, 2016 /EINPresswire.com/ — After spending over a year at the studio in Cotati, CA recording with his band, Lior Ben-Hur announces the release of a full-length album, So I Wander. The album is produced by Marcus Urani (Groundation & Rising Tide), mixed and mastered by Jim Fox (Lion and Fox recording studios) and features special collaborations with artists Kumar Bent (Raging Fyah), Jah Levi, Rasta elder Mutabaruka, Yossi Fine, Iraqi-Israeli world music expert, Yair Dalal and the accomplished Palestinian rapper, Saz.

Born in Jerusalem with Greek and Iraqi roots, Lior Ben-Hur travels internationally where he spends time learning, performing and sharing experiences with musicians and artists from around the globe. These extensive travels and experiences are the inspiration for the new album, So I Wander.

The title song of the album, So I Wander, was first released as a single in 2015 and won Best Reggae Song on Akademia Music Awards for December 2015. This song was the band’s first collaboration with the accomplished Reggae musician Marcus Urani (Groudation & Rising Tide), who is featured on piano and keyboards. Lior Ben-Hur offers a free download of this single, which can be found using the link below: http://www.liorbenhur.com/free-downloads

Lior Ben-Hur and his 8-piece San Francisco-based band, Sol Tevél, spread positive messages, uplifting melodies and a unique refreshing approach to Reggae music. In June 2015, the band released their self-titled Reggae EP, and have since shared the stage with legendary Roots Reggae artists such as; Stephen Marley, Black Uhuru, Tarrus Riley, Groundation, Richie Spice and Don Carlos.

Lior Ben-Hur
4157937417
email us here
Lior Ben-Hur

Roads of Creation- Lior Ben-Hur


Source: EIN Presswire